A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane
Phase of Trial: Phase IV
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 21 Aug 2017 Planned End Date changed from 1 Jan 2019 to 2 Dec 2020.
- 21 Aug 2017 Planned primary completion date changed from 1 Jan 2019 to 2 Dec 2020.
- 15 Jun 2017 Planned End Date changed from 31 Dec 2018 to 1 Jan 2019.